SCHEDULE 13G/A: Lance Friedman Discloses 8.55% Stake in Aspire Biopharma Holdings
Beneficial Ownership Disclosure
Lance Friedman has filed an amended Schedule 13G, revealing beneficial ownership of 8.55% of Aspire Biopharma Holdings, Inc.'s common stock as of April 4, 2025.
Summary
- Lance Friedman reported beneficial ownership of 4,183,375 shares of common stock in Aspire Biopharma Holdings, Inc.
- This ownership represents 8.55% of the company's common stock.
- The reported shares include holdings by Blackstone Capital Advisors, Inc. (1,680,886 shares), Cobra Alternative Strategies LLC (1,839,989 shares), and Thor Special Situations LLC (662,500 shares).
- Friedman holds sole voting power and sole dispositive power over all 4,183,375 shares.
- This filing is an Amendment No. 5 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant stake by an individual investor, potentially indicating confidence or strategic interest in the company.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of event which requires filing of this statement |
| 04/11/2025 | Date of filing of this statement |
Keywords
Aspire Biopharma Holdings, Lance Friedman, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Shareholder, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.